through clinical trials
The world’s most extensive program of in-human NMN research.
We are advancing a broad and diverse pipeline of small molecule therapies to address significant health- and lifespan associated conditions, and to develop treatment options for some of the most prevalent age-associated conditions and diseases.
Our pipeline is comprised of multiple preclinical and clinical-stage therapeutic candidates that have the potential to deliver optimal benefits while maintaining a strong safety profile.
|Study design||Expected completion date|
|Skin anti-aging||40 participants - 28 days - 5% nmn cream||Completed|
|Skin health||60 participants - 56 days - 2% nmn cream||Completed|
|Physical capacity and muscle recovery||150 participants - 38 days - placebo/NMN 250mg/NMN 500mg||Ongoing|
|Tolerance & NAD+ levels||20 participants - 30 days - NMN 400mg||Completed|
|Pharmacokinetics||24 participants - 30 days - NMN 400mg||Q4 2022|
|Lipid and glucose management||80 participants - 120 days - placebo/NMN 800m||Q3 2022|
|Senior healthspan extension NMN vs NR||200 participants - 360 days - placebo/NMN 750mg||Q4 2022|
|Immune health||200 participants - 120 days - placebo/NMN 600mg||Q3 2022|